BUY NOW For Sale 70%!
buy viagra

Case 1845c for sale in uk zithromax

case

Edition:

close

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel

https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cDovL3JlZmVyZW5jZS5tZWRzY2FwZS5jb20vZHJ1Zy90YW1pZmx1LW9zZWx0YW1pdmlyLTM0MjYxOA==

processing....

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

capsule

  • 30mg
  • 45mg
  • 75mg

powder for oral suspension

  • 6mg/mL

more...

Influenza A and B Prophylaxis

75 mg PO qDay for at least 10 days

Dosing considerations

  • Initiate within 48 hours of exposure
  • For community outbreak, may administer for up to 6 weeks

Influenza A and B Treatment

75 mg PO q12hr x5 days

Dosing considerations

  • Initiate within 48 hours of influenza symptom onset

H1N1 Influenza A (Swine Flu) Prophylaxis (Off-label)

75 mg PO qDay

Dosing considerations

  • Postexposure prophylaxis: Initiate within 7 days of exposure and continue for at least 10 days
  • Preexposure prophylaxis (community outbreak): Initiate during potential exposure period and continue for 10 days after last known exposure

H1N1 Influenza A (Swine Flu) Treatment (Off-label)

75 mg PO q12hr x5 days

Dosing considerations

  • Initiate within 48 hours of influenza symptom onset

Dosing Modifications

Renal impairment

  • Treatment
    • CrCl >60 mL/min: No dosage adjustment necessary
    • CrCl >30 to 60 mL/min: 30 mg PO BID
    • CrCl >10 to 30 mL/min: 30 mg PO qDay
    • End-stage renal disease (not undergoing dialysis): Not recommended (not studied)
  • Prophylaxis
    • CrCl >60 mL/min: No dose adjustment necessary
    • CrCl >30 to 60 mL/min: 30 mg PO qDay
    • CrCl >10 to 30 mL/min: 30 mg PO every other day
    • End-stage renal disease (not undergoing dialysis): Not recommended (not studied)

Dosage Forms & Strengths

capsule

  • 30mg
  • 45mg
  • 75mg

powder for oral suspension

  • 6mg/mL

more...

Influenza A and B Prophylaxis

<1 year: Safety and efficacy not established for prophylaxis

≥1 year

  • <15 kg: 30 mg PO qDay x10 days
  • 15-23 kg: 45 mg PO qDay x10 days
  • 23-40 kg: 60 mg PO qDay x10 days
  • >40 kg: 75 mg PO qDay x10 days

Dosing considerations

  • Start within 2 days of exposure

Influenza A and B Treatment

<2 weeks: Safety and efficacy not established for treatment

Aged 2 weeks to <1 year

  • 3 mg/kg PO BID x5 days

≥1 year

  • <15 kg: 30 mg PO q12hr x5 days
  • 15-23 kg: 45 mg PO q12hr x5 days
  • 23-40 kg: 60 mg PO q12hr x5 days
  • >40 kg: 75 mg PO q12hr x5 days

Dosing considerations

  • Start within 24-48 hours of symptom onset

H1N1 Influenza A (Swine Flu) Prophylaxis (Off-label)

<1 year

  • <3 months: Data limited; not recommended unless situation judged critical
  • 3-5 months: 20 mg PO qDay x10 days
  • 6-11 months: 25 mg PO qDay x10 days

≥1 year

  • <15 kg: 30 mg PO qDay x10 days
  • 15-23 kg: 45 mg PO qDay x10 days
  • 23-40 kg: 60 mg PO qDay x10 days
  • >40 kg: Administer as in adults

H1N1 Influenza A (Swine Flu) Treatment (Off-label)

Acute illness and age <1 year

  • <3 months: 12 mg PO q12hr x5 days
  • 3-5 months: 20 mg PO q12hr x5 days
  • 6-11 months: 25 mg PO q12hr x5 days

Acute illness and age ≥1 year

  • <15 kg: 30 mg PO q12hr x5 days
  • 15-23 kg: 45 mg PO q12hr x5 days
  • 23-40 kg: 60 mg PO q12hr x5 days
  • >40 kg: Administer as in adults

Interactions

Interaction Checker

Enter a drug name and oseltamivir

No Results

 activity indicator 

No Interactions Found

Interactions Found

Contraindicated

Serious - Use Alternative

All Interactions Sort By: Severity Name
 activity indicator 

Previous

Next:

Adverse Effects

1-10%

Abdominal pain

Conjunctivitis

Ear disorder

Epistaxis

Insomnia

Nausea

Vomiting

Vertigo

<1%

Aggravation of diabetes

Anemia

Arrhythmia

Confusion

Delirium

Hemorrhagic colitis

Hepatitis

Humerus fracture

Peritonsillar abscess

Pneumonia

Pseudomembranous colitis

Pyrexia

Rash

Seizure

Transaminases increased

Toxic epidermal necrolysis

Unstable angina

Swelling of face or tongue

Postmarketing Reports

Hypothermia

Diaper rash (2 weeks to <1 year of age)

Dermatitis

Urticaria

Eczema

Stevens-Johnson Syndrome

Erythema multiforme

Gastrointestinal bleeding

Abnormal liver function tests

Previous

Next:

Warnings

Contraindications

Hypersensitivity

Cautions

Use caution in patients with chronic cardiac disease, severre hepatic impairment, renal imapairment, respiratory disease

Most effective when used within 24-48 hr of onset of symptoms

Age <1 year: Safety and efficacy for PROPHYLAXIS of influenza has not been established

Oral suspension should be mixed prior to dispensing

Safety and efficacy in immunocompromised patients not established

Therapy is not a substitute for influenza virus vaccine

Serious skin/hypersensitivity reactions such as Stevens-Johnson Syndrome, toxic epidermal necrolysis and erythema multiforme; discontinue therapy and initiate appropriate treatment if allergic-like reactions occur or are suspected

Patients with influenza, including those receiving therapy, particularly pediatric patients, may be at an increased risk of confusion or abnormal behavior early in their illness, potentially fatal neuropsychiatric adverse events; monitor for signs of abnormal behavior

Prescribers should be alert to potential for secondary bacterial infections and treat them as appropriate

Oral suspension and hereditary fructose intolerance

  • Fructose can be harmful to patients with hereditary fructose intolerance
  • One dose of 75 mg oral suspension delivers 2 g of sorbitol; this is above the daily maximum limit of sorbitol for patients with hereditary fructose intolerance, and may cause dyspepsia and diarrhea

Previous

Next:

Pregnancy & Lactation

Pregnancy category: C

Prompt use of antiviral drugs during the 2009 H1N1 influenza pandemic improved survival among severely ill pregnant women; the CDC examined reports of severe flu (resulting in death or ICU admission) in 347 pregnant women during the pandemic; only 4 women (7%) of those who died received an antiviral within 2 days of symptom onset, compared with 41% of survivors. (MMWR Sept 9, 2011;60[35]:1192-6)

Lactation: Unknown; use caution

Pregnancy Categories

more...

Previous

Next:

Pharmacology

Mechanism of Action

Inhibits viral neuraminidases; stops release of virus from cells and prevents virus from crossing mucous lining of respiratory tract

Absorption

Bioavailability: 75%

Peak plasma time: 2.5-6 hr

Distribution

Protein bound: 3% (oseltamivir carboxylase); 42% (oseltamivir)

Vd: 23-26 L

Elimination

Half-life: 1-3hr (oseltamivir); 6-10 hr (oseltamivir carboxylate)

Excretion: Feces; urine (>90% as oseltamivir carboxylate)

Previous

Next:

Administration

Oral Administration

Tablets and oral suspension may be take with or without food

Tolerability may be enhanced if taken with food

Emergency Preparation of Oral Suspension from 75 mg Capsules

Instructions below are for 100 mL of 6 mg/mL suspension

1. Place 7 mL of distilled water into a polyethyleneterephthalate (PET) or glass bottle

2. Empty content of eight 75-mg capsules (ie, 600 mg) into bottle

3. Gently swirl the suspension to ensure adequate wetting of the powder for at least 2 minutes

4. Slowly add 91 mL of Ora-Sweet, cherry syrup, or simple syrup

5. Close bottle and shake well for about 30 minutesInstruct patient to shake well before use

Stable for 5 days at room temperature or 5 weeks refrigerated at 2-8°C (36-46°F)

Previous

Next:

Images

loading Pricing and Images

Previous

Next:

Patient Handout

activity indicator
activity indicator

Previous

Next:

Formulary

FormularyPatient Discounts

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Plans
Non-Medicare Plans Medicare Plans

Done

CLOSE

Additional Offers

Previous

What would you like to print?

Source: http://reference.medscape.com/drug/tamiflu-oseltamivir-342618


BUY NOW For Sale 70%!
buy viagra

Interakcje tabletek antykoncepcyjnych z lekami/dietami, itp Zithromax 250 mg pfizer pharmaceuticals

Case 1845c for sale in uk zithromax FDA Statement regarding azithromycin (Zithromax) and the risk of
Case 1845c for sale in uk zithromax Azithromycin. A review of its antimicrobial activity, pharmacokinetic
Case 1845c for sale in uk zithromax Azithromycin 250 mg, 500 mg, 1000 mg tablets Buy Zithromax Now
Case 1845c for sale in uk zithromax Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by
Case 1845c for sale in uk zithromax Zithromax shelf life m Personal Development
Case 1845c for sale in uk zithromax Essay on animal protection - Class Masaj Dalaman
Case 1845c for sale in uk zithromax Tips : (Grease Trap)
BUY NOW For Sale 70%!
buy viagra